

S5 Table. Outcomes of reported studies regarding bulky nodal disease in uterine cervix, oral cavity, and oropharyngeal cancer

Type of cancer	No. of patients	No. of patients with bulky nodal disease (criteria for bulky disease)	Radiation dose	Outcomes
Uterine cervix [1]	161	70 (> 2 cm)	46-60 Gy	Increased regional recur (HR 1.9)
Uterine cervix [2]	208	22 (> 2 cm)	66.9-74.1 Gy	Pelvic recur 2/22 (total 5/208)
Uterine cervix [3]	151	151 (\geq 1.5 cm)		Survival 45% in median follow-up of 45 mo
Oral cavity [4]	14,554	2,665 (> 2 cm)	N/A	Poor OS of HR 2.14-2.35 but not in MVA
Oropharynx [5]	1,907	133 (> 6 cm)	N/A	5-Year OS 59% (compared to 80%-83%)
Oropharynx [6]	156	79 (> 6 cm)	N/A	3-Year DFS 88% (100% for non-bulky)

DFS, disease-free survival; HR, hazard ratio; N/A, not available; OS, overall survival.

References

1. Tiwari R, Narayanan GS, Reddy VP, Vishwanathan B, Narayanan S, Venugopal R. Impact of nodal boost irradiation and MR-based brachytherapy on oncologic outcomes in node-positive cervical cancer. *Gynecol Oncol.* 2021;163:110-6.
2. Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. *Int J Radiat Oncol Biol Phys.* 2004;59:706-12.
3. Olthof EP, Wenzel H, van der Velden J, Spijkerboer AM, Bekkers R, Beltman JJ, et al. Treatment of bulky lymph nodes in locally advanced cervical cancer: boosting versus debulking. *Int J Gynecol Cancer.* 2022;32:861-8.
4. Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, Scher KS, et al. Metastatic lymph node burden and survival in oral cavity cancer. *J Clin Oncol.* 2017;35:3601-9.
5. O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. *Lancet Oncol.* 2016;17:440-51.
6. Spector ME, Gallagher KK, Bellile E, Chinn SB, Ibrahim M, Byrd S, et al. Patterns of nodal metastasis and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma. *Head Neck.* 2014;36:1233-40.